Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy
收藏NIAID Data Ecosystem2026-03-13 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2720538
下载链接
链接失效反馈官方服务：
资源简介：
This study will explore the efficacy and safety of tislelizumab (PD1 inhibitor) combined with DisitamabVedotin (ADC) and pyrotinib maleate (TKI) in the treatment of HER2-positive or mutated advanced colorectal cancer who have failed standard therapy .
创建时间：
2022-06-15
